Overview

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Status:
Recruiting
Trial end date:
2024-03-11
Target enrollment:
Participant gender:
Summary
This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD). Participants will be randomized to receive either inclacumab or placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Global Blood Therapeutics